Molecular Diagnostics in Cancer Testing 2016 - Molecular Diagnostics for Cancer Testing Offers One of the Brightest Areas for Growth and Innovation

Dublin, Jan. 13, 2016 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/3dbr5j/molecular) has announced the addition of the "Molecular Diagnostics in Cancer Testing" report to their offering.

Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being continually added. The technologies that come under the umbrella of molecular diagnostics include first-generation amplification, DNA probes, fluorescent in-situ hybridization (FISH), second-generation biochips and microfluidics, next-generation signal detection, biosensors and molecular labels, and gene expression profiling using microarrays.

These technologies are improving the discovery of therapeutic molecules for cancer, the screening, diagnosis and classification of cancer patients, and the optimization of drug therapy. This report describes the specific segment of the in vitro diagnostics (IVD) market known as molecular diagnostics (MD), with a specialization in the MD tests for cancer. In the current medical diagnostics market, molecular diagnostics for cancer testing offers one of the brightest areas for growth and innovation.

The confluence of breakthroughs in genomics, proteomics, and the development of microarray devices to measure analytes in the blood and various body tissues, has led to this revolutionary market segment offering the power of advanced analytical techniques to the diagnosis and treatment of cancer. This report analyzes the size and growth of the molecular diagnostics market in its applications for cancer detection and therapy, examining the factors that influence the various market segments and the dollar volume of sales, both in the United States and worldwide.

Key Topics Covered:

1. Overview

2. Introduction to Molecular Diagnostics

3. Cancer Diagnostics Molecular Testing Market

4. Molecular Diagnostic Tests for Cancer

5. Business

6. Reimbursement and Billing

7. Government Regulation

8. Business Decisions Using Molecular Diagnostic Tests in Cancer Test Development

9. Company Profiles

Companies Mentioned

• Abbott Molecular Diagnostics
• Accugenomics, Inc.
• Agendia
• Ambry Genetics
• Biodesix
• bioMérieux
• bioTheranostics (AviaraDx)
• Cancer Genetics, Inc.
• Clarient, Inc. (GE Healthcare)
• Counsyl
• Flatiron Health
• Epigenomics
• Exact Sciences Corporation
• Exiqon
• Genomic Health, Inc.
• Genoptix, Inc. (Novartis)
• Genmark Diagnostics
• Genomictree
• HTG Molecular Diagnostics
• Invitae
• LabCorp
• Myriad Genetics, Inc.
• Nanostring
• Neogenomics
• NSTG
• Nuvera Biosciences
• Orion Genomics
• Pathway Genomics
• Personal Genome Diagnostics
• Quest Diagnostics
• Rosetta Genomics Ltd.
• Signal Genetics
• Source MDx
• Wilex, Inc.
  

For more information visit http://www.researchandmarkets.com/research/3dbr5j/molecular

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

         Sector: In Vitro Diagnostics, Molecular Diagnostics